Advertisement
American Journal of Kidney Diseases

Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis

      Chronic kidney disease (CKD) affects approximately 500 million people worldwide and is increasingly common in both industrialized and emerging countries. Although the mechanisms underlying the inexorable progression of CKD are incompletely defined, recent discoveries may pave the way to a more comprehensive understanding of the pathophysiology of CKD progression and the development of new therapeutic strategies. In particular, there is accumulating evidence indicating a key role for the complex and yet incompletely understood system of divalent cation regulation, which includes phosphate metabolism and the recently discovered fibroblast growth factor 23 (FGF-23)/klotho system, which seems inextricably associated with vitamin D deficiency. The aim of this review is to discuss the links between high blood pressure, proteinuria, phosphate levels, and CKD progression and explore new therapeutic strategies to win the fight against CKD.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Couser W.G.
        • Remuzzi G.
        • Mendis S.
        • Tonelli M.
        The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.
        Kidney Int. 2011; 80: 1258-1270
        • International Society of Nephrology
        A briefing on the global impact of kidney disease. 2011.
        (Accessed February 15, 2013)
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • McCulloch C.E.
        • Hsu C.Y.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305
        • Wuhl E.
        • Schaefer F.
        • Medscape
        Managing kidney disease with blood-pressure control.
        Nat Rev Nephrol. 2011; 7: 434-444
        • Rahman M.
        • Pressel S.
        • Davis B.R.
        • et al.
        Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
        Ann Intern Med. 2006; 144: 72-180
        • Ruggenenti P.
        • Perna A.
        • Mosconi L.
        • Pisoni R.
        • Remuzzi G.
        Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies.
        Kidney Int. 1998; 53: 1209-1216
        • de Zeeuw D.
        • Remuzzi G.
        • Parving H.H.
        • et al.
        Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
        Circulation. 2004; 110: 921-927
        • World Health Organization
        Global health risks: mortality and burden of disease attributable to selected major risks. 2009.
        (Accessed February 15, 2013)
        • Paul M.
        • Poyan Mehr A.
        • Kreutz R.
        Physiology of local renin-angiotensin systems.
        Physiol Rev. 2006; 86: 747-803
        • Klag M.J.
        • Whelton P.K.
        • Randall B.L.
        • et al.
        Blood pressure and end-stage renal disease in men.
        N Engl J Med. 1996; 334: 13-18
        • Tozawa M.
        • Iseki K.
        • Iseki C.
        • Kinjo K.
        • Ikemiya Y.
        • Takishita S.
        Blood pressure predicts risk of developing end-stage renal disease in men and women.
        Hypertension. 2003; 41: 1341-1345
        • Cravedi P.
        • Ruggenenti P.
        • Remuzzi G.
        Which antihypertensive drugs are the most nephroprotective and why?.
        Expert Opin Pharmacother. 2010; 11: 2651-2663
        • Klahr S.
        • Levey A.S.
        • Beck G.J.
        • et al.
        The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease.
        N Engl J Med. 1994; 330: 877-884
        • Toto R.D.
        • Mitchell H.C.
        • Smith R.D.
        • Lee H.C.
        • McIntire D.
        • Pettinger W.A.
        “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis.
        Kidney Int. 1995; 48: 851-859
        • Wright J.T.
        • Bakris G.
        • Greene T.
        • et al.
        Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
        JAMA. 2002; 288: 2421-2431
        • Ruggenenti P.
        • Perna A.
        • Loriga G.
        • et al.
        Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
        Lancet. 2005; 365: 939-946
        • Peterson J.C.
        • Adler S.
        • Burkart J.M.
        • et al.
        Blood pressure control, proteinuria, and the progression of renal disease.
        Ann Intern Med. 1995; 123: 754-762
        • British Renal Association Society Guidelines
        Detection, monitoring and care of patients with CKD. 2011.
        (Accessed February 15, 2013)
        • Anderson S.
        • Meyer T.W.
        • Rennke H.G.
        • Brenner B.M.
        Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
        J Clin Invest. 1985; 76: 612-619
        • Deyneli O.
        • Yavuz D.
        • Velioglu A.
        • et al.
        Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients.
        J Renin Angiotensin Aldosterone Syst. 2006; 7: 98-103
        • Lewis E.J.
        • Hunsicker L.G.
        • Bain R.P.
        • Rohde R.D.
        The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
        N Engl J Med. 1993; 329: 1456-1462
        • Matsushita K.
        • van der Velde M.
        • Astor B.C.
        • et al.
        Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
        Lancet. 2010; 375: 2073-2081
      1. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.
        Lancet. 1997; 349: 1857-1863
        • Hovind P.
        • Rossing P.
        • Tarnow L.
        • Toft H.
        • Parving J.
        • Parving H.H.
        Remission of nephrotic-range albuminuria in type 1 diabetic patients.
        Diabetes Care. 2001; 24: 1972-1977
        • Atkins R.C.
        • Briganti E.M.
        • Lewis J.B.
        • et al.
        Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
        Am J Kidney Dis. 2005; 45: 281-287
        • Keane W.F.
        • Zhang Z.
        • Lyle P.A.
        • et al.
        Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL Study.
        Clin J Am Soc Nephrol. 2006; 1: 761-767
        • Remuzzi G.
        • Benigni A.
        • Remuzzi A.
        Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.
        J Clin Invest. 2006; 116: 288-296
        • Parving H.H.
        • Lehnert H.
        • Brochner-Mortensen J.
        • Gomis R.
        • Andersen S.
        • Arner P.
        The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
        N Engl J Med. 2001; 345: 870-878
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • Maschio G.
        • Alberti D.
        • Janin G.
        • et al.
        Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency.
        N Engl J Med. 1996; 334: 939-945
        • Cravedi P.
        • Ruggenenti P.
        • Remuzzi G.
        Proteinuria should be used as a surrogate in CKD.
        Nat Rev Nephrol. 2012; 8: 301-306
        • Remuzzi G.
        • Ruggenenti P.
        • Benigni A.
        Understanding the nature of renal disease progression.
        Kidney Int. 1997; 51: 2-15
        • Levey A.S.
        • de Jong P.E.
        • Coresh J.
        • et al.
        The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
        Kidney Int. 2011; 80: 17-28
        • Chronic Kidney Disease Prognosis Consortium
        Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
        Lancet. 2010; 375: 2073-2081
        • Iseki K.
        • Iseki C.
        • Ikemiya Y.
        • Fukiyama K.
        Risk of developing end-stage renal disease in a cohort of mass screening.
        Kidney Int. 1996; 49: 800-805
        • Iseki K.
        • Ikemiya Y.
        • Iseki C.
        • Takishita S.
        Proteinuria and the risk of developing end-stage renal disease.
        Kidney Int. 2003; 63: 1468-1474
        • Ishani A.
        • Grandits G.A.
        • Grimm R.H.
        • et al.
        Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial.
        J Am Soc Nephrol. 2006; 17: 1444-1452
        • Retnakaran R.
        • Cull C.A.
        • Thorne K.I.
        • Adler A.I.
        • Holman R.R.
        • UKPDS Study Group
        Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
        Diabetes. 2006; 55: 1832-1839
        • Ruggenenti P.
        • Perna A.
        • Remuzzi G.
        • GISEN Group Investigators
        Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.
        Kidney Int. 2003; 63: 2254-2261
        • Ninomiya T.
        • Perkovic V.
        • Verdon C.
        • et al.
        Proteinuria and stroke: a meta-analysis of cohort studies.
        Am J Kidney Dis. 2009; 53: 417-425
        • Bello A.K.
        • Hemmelgarn B.
        • Lloyd A.
        • et al.
        Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes.
        Clin J Am Soc Nephrol. 2011; 6: 1418-1426
        • Hallan S.I.
        • Ritz E.
        • Lydersen S.
        • Romundstad S.
        • Kvenild K.
        • Orth S.R.
        Combining GFR and albuminuria to classify CKD improves prediction of ESRD.
        J Am Soc Nephrol. 2009; 20: 1069-1077
        • van der Velde M.
        • Matsushita K.
        • Coresh J.
        • et al.
        Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality.
        Kidney Int. 2011; 79: 1341-1352
        • Myrvang H.
        Progression of renal disease: high salt intake blunts the benefit of ACE inhibitors and accelerates renal function decline.
        Nat Rev Nephrol. 2012; 8: 61
        • Ruggenenti P.
        • Perna A.
        • Tonelli M.
        • et al.
        Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
        Clin J Am Soc Nephrol. 2010; 5: 1928-1938
        • Zoja C.
        • Corna D.
        • Camozzi D.
        • et al.
        How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.
        J Am Soc Nephrol. 2002; 13: 2898-2908
        • Ruggenenti P.
        • Perticucci E.
        • Cravedi P.
        • et al.
        Role of remission clinics in the longitudinal treatment of CKD.
        J Am Soc Nephrol. 2008; 19: 1213-1224
        • Daina E.
        • Gamba S.
        • Ruggenenti P.
        • et al.
        Effects of the remission clinic approach in Alport syndrome: results from a prospective, sequential cohort study. American Society of Nephrology (ASN) Kidney Week. 2012.
        (Accessed February 15, 2013)
        • Ibels L.S.
        • Alfrey A.C.
        • Haut L.
        • Huffer W.E.
        Preservation of function in experimental renal disease by dietary restriction of phosphate.
        N Engl J Med. 1978; 298: 122-126
        • Barsotti G.
        • Morelli E.
        • Giannoni A.
        • Guiducci A.
        • Lupetti S.
        • Giovannetti S.
        Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: a controlled trial.
        Kidney Int Suppl. 1983; 16: S278-S284
        • Zoccali C.
        • Ruggenenti P.
        • Perna A.
        • et al.
        Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.
        J Am Soc Nephrol. 2011; 22: 1923-1930
        • John G.B.
        • Cheng C.Y.
        • Kuro-o M.
        Role of klotho in aging, phosphate metabolism, and CKD.
        Am J Kidney Dis. 2011; 58: 127-134
        • Uribarri J.
        • Calvo M.S.
        Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?.
        Semin Dial. 2003; 16: 186-188
        • Isakova T.
        • Gutierrez O.M.
        • Smith K.
        • et al.
        Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
        Nephrol Dial Transplant. 2011; 26: 584-591
        • Moe S.M.
        • Zidehsarai M.P.
        • Chambers M.A.
        • et al.
        Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.
        Clin J Am Soc Nephrol. 2011; 6: 257-264
        • Saito H.
        • Maeda A.
        • Ohtomo S.
        • et al.
        Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.
        J Biol Chem. 2005; 80: 2543-2549
        • Shuto E.
        • Taketani Y.
        • Tanaka R.
        • et al.
        Dietary phosphorus acutely impairs endothelial function.
        J Am Soc Nephrol. 2009; 20: 1504-1512
        • Martin A.
        • David V.
        • Quarles L.D.
        Regulation and function of the FGF23/klotho endocrine pathways.
        Physiol Rev. 2012; 92: 131-155
        • Wolf M.
        Update on fibroblast growth factor 23 in chronic kidney disease.
        Kidney Int. 2012; 82: 737-747
        • Liu S.
        • Tang W.
        • Zhou J.
        • et al.
        Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.
        J Am Soc Nephrol. 2006; 17: 1305-1315
        • Gattineni J.
        • Bates C.
        • Twombley K.
        • et al.
        FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
        Am J Physiol Renal Physiol. 2009; 297: F282-F291
        • Yilmaz M.I.
        • Sonmez A.
        • Saglam M.
        • et al.
        FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.
        Kidney Int. 2010; 78: 679-685
        • Li Y.C.
        • Kong J.
        • Wei M.
        • Chen Z.F.
        • Liu S.Q.
        • Cao L.P.
        1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.
        J Clin Invest. 2002; 110: 229-238
        • De Borst M.H.
        • Vervloet M.G.
        • Ter Wee P.M.
        • Navis G.
        Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease.
        J Am Soc Nephrol. 2011; 22: 1603-1609
        • Kendrick J.
        • Cheung A.K.
        • Kaufman J.S.
        • et al.
        FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.
        J Am Soc Nephrol. 2011; 22: 1913-1922
        • Faul C.
        • Amaral A.P.
        • Oskouei B.
        • et al.
        FGF23 induces left ventricular hypertrophy.
        J Clin Invest. 2011; 121: 4393-4408
        • Lavi-Moshayoff V.
        • Wasserman G.
        • Meir T.
        • Silver J.
        • Naveh-Many T.
        PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.
        Am J Physiol Renal Physiol. 2010; 299: F882-F889
        • Dusso A.
        • Arcidiacono M.V.
        • Yang J.
        • Tokumoto M.
        Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality.
        J Steroid Biochem Mol Biol. 2010; 121: 193-198
        • Moreno J.A.
        • Izquierdo M.C.
        • Sanchez-Nino M.D.
        • et al.
        The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB.
        J Am Soc Nephrol. 2011; 22: 1315-1325
        • Mitani H.
        • Ishizaka N.
        • Aizawa T.
        • et al.
        In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage.
        Hypertension. 2002; 39: 838-843
        • Black R.A.
        • Rauch C.T.
        • Kozlosky C.J.
        • et al.
        A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.
        Nature. 1997; 385: 729-733
        • Melenhorst W.B.
        • Visser L.
        • Timmer A.
        • van den Heuvel M.C.
        • Stegeman C.A.
        • van Goor H.
        ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability?.
        Am J Physiol Renal Physiol. 2009; 297: F781-F790
        • Dusso A.
        • Gonzalez E.A.
        • Martin K.J.
        Vitamin D in chronic kidney disease.
        Best Pract Res Clin Endocrinol Metab. 2011; 25: 647-655
        • Dusso A.S.
        Renal vitamin D receptor expression and vitamin D renoprotection.
        Kidney Int. 2012; 81: 937-939
        • Weil E.J.
        • Lemley K.V.
        • Mason C.C.
        • et al.
        Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
        Kidney Int. 2012; 82: 1010-1017
        • Remuzzi G.
        • Bertani T.
        Pathophysiology of progressive nephropathies.
        N Engl J Med. 1998; 339: 1448-1456
        • Ruggenenti P.
        • Cravedi P.
        • Remuzzi G.
        Mechanisms and treatment of CKD.
        J Am Soc Nephrol. 2012; 23: 1917-1928
        • Zoja C.
        • Morigi M.
        • Figliuzzi M.
        • et al.
        Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins.
        Am J Kidney Dis. 1995; 26: 934-941
        • Drumm K.
        • Bauer B.
        • Freudinger R.
        • Gekle M.
        Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1).
        Cell Physiol Biochem. 2002; 12: 187-196
        • Tang S.
        • Leung J.C.
        • Abe K.
        • et al.
        Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo.
        J Clin Invest. 2003; 111: 515-527
        • Abbate M.
        • Zoja C.
        • Remuzzi G.
        How does proteinuria cause progressive renal damage?.
        J Am Soc Nephrol. 2006; 17: 2974-2984
        • Barnes J.L.
        • Gorin Y.
        Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases.
        Kidney Int. 2011; 79: 944-956
        • Johnson D.W.
        • Saunders H.J.
        • Baxter R.C.
        • Field M.J.
        • Pollock C.A.
        Paracrine stimulation of human renal fibroblasts by proximal tubule cells.
        Kidney Int. 1998; 54: 747-757
        • Biancone L.
        • David S.
        • Della Pietra V.
        • Montrucchio G.
        • Cambi V.
        • Camussi G.
        Alternative pathway activation of complement by cultured human proximal tubular epithelial cells.
        Kidney Int. 1994; 45: 451-460
        • Nangaku M.
        • Pippin J.
        • Couser W.G.
        Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome.
        J Am Soc Nephrol. 1999; 10: 2323-2331
        • Rangan G.K.
        • Pippin J.W.
        • Coombes J.D.
        • Couser W.G.
        C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria.
        Kidney Int. 2005; 67: 492-503
        • Kim H.J.
        • Vaziri N.D.
        Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure.
        Am J Physiol Renal Physiol. 2010; 298: F662-F671
        • Laouari D.
        • Burtin M.
        • Phelep A.
        • et al.
        A transcriptional network underlies susceptibility to kidney disease progression.
        EMBO Mol Med. 2012; 4: 825-839
        • Rodriguez-Iturbe B.
        • Vaziri N.D.
        • Herrera-Acosta J.
        • Johnson R.J.
        Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all.
        Am J Physiol Renal Physiol. 2004; 286: F606-F616
        • Cozzolino M.
        • Lu Y.
        • Finch J.
        • Slatopolsky E.
        • Dusso A.S.
        p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
        Kidney Int. 2001; 60: 2109-2117
        • Lautrette A.
        • Li S.
        • Alili R.
        • et al.
        Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach.
        Nat Med. 2005; 11: 867-874
        • Xiang W.
        • Kong J.
        • Chen S.
        • et al.
        Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems.
        Am J Physiol Endocrinol Metab. 2005; 288: E125-E132
        • Bodyak N.
        • Ayus J.C.
        • Achinger S.
        • et al.
        Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals.
        Proc Natl Acad Sci U S A. 2007; 104: 16810-16815
        • Kuhlmann A.
        • Haas C.S.
        • Gross M.L.
        • et al.
        1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat.
        Am J Physiol Renal Physiol. 2004; 286: F526-F533
        • He W.
        • Kang Y.S.
        • Dai C.
        • Liu Y.
        Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.
        J Am Soc Nephrol. 2011; 22: 90-103
        • Lau W.L.
        • Leaf E.M.
        • Hu M.C.
        • et al.
        Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.
        Kidney Int. 2012; 82: 1261-1270
        • Wolf M.
        • Shah A.
        • Gutierrez O.
        • et al.
        Vitamin D levels and early mortality among incident hemodialysis patients.
        Kidney Int. 2007; 72: 1004-1013
        • de Zeeuw D.
        • Agarwal R.
        • Amdahl M.
        • et al.
        Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
        Lancet. 2010; 376: 1543-1551
        • Cheng J.
        • Zhang W.
        • Zhang X.
        • Li X.
        • Chen J.
        Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
        Clin J Am Soc Nephrol. 2012; 7: 391-400
        • Alborzi P.
        • Patel N.A.
        • Peterson C.
        • et al.
        Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.
        Hypertension. 2008; 52: 249-255
        • Fishbane S.
        • Chittineni H.
        • Packman M.
        • Dutka P.
        • Ali N.
        • Durie N.
        Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
        Am J Kidney Dis. 2009; 54: 647-652
        • Block G.A.
        • Klassen P.S.
        • Lazarus J.M.
        • Ofsthun N.
        • Lowrie E.G.
        • Chertow G.M.
        Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
        J Am Soc Nephrol. 2004; 15: 2208-2218
        • Kestenbaum B.
        • Sampson J.N.
        • Rudser K.D.
        • et al.
        Serum phosphate levels and mortality risk among people with chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 520-528
        • Ix J.H.
        • Shlipak M.G.
        • Wassel C.L.
        • Whooley M.A.
        Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study.
        Nephrol Dial Transplant. 2010; 25: 993-997
        • Cozzolino M.
        • Staniforth M.E.
        • Liapis H.
        • et al.
        Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
        Kidney Int. 2003; 64: 1653-1661
        • Cozzolino M.
        • Dusso A.S.
        • Liapis H.
        • et al.
        The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
        J Am Soc Nephrol. 2002; 13: 2299-2308